Among these inhibitors, Ivosidenib is undoubtedly the most “developed” IDH inhibitor in CCA, with fatigue, nausea, diarrhoea, abdominal discomfort, decreased appetite, and vomiting being the most often reported adverse effects [30]. Here, IDH1 is linked to cholangiocarcinoma.